Proficiency Testing/EQA / 2024 Surveys / Genetics and Molecular Pathology / Molecular Oncology-Hematologic Help Please log in to determine if you are eligible to purchase PT Programs. MEASURABLE (MINIMAL) RESIDUAL DISEASE - MRD2 Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS). Analyte Challenges per Shipment Number of Shipments PML::RARA 3 Two shipments per year Program Information Three RNA specimens in sterile water For laboratories diagnosing and monitoring leukemia tumor burden by measuring the quantity of PML::RARA fusion transcripts Ships on dry ice Shipping Schedule Shipment A: April 16 Shipment B: October 1 Guest Log in/Register Customers Who Bought This Item Also Bought B-ALL MEASURABLE (MINIMAL) RESIDUAL DISEASE VIEW DETAILS >